<DOC>
	<DOCNO>NCT03000296</DOCNO>
	<brief_summary>This study evaluate safety clinical benefit therapeutic approach condition regimen Cyclophosphamide ( Cy ) + Thymoglobulin r ( ATG ) + Granulocyte Colony-Stimulating Factor ( G-CSF ) follow autologous Hematopoietic Stem Cell Transplantaion ( HSCT ) rescue therapy refractory Crohn 's disease . It count adverse event , clinical endoscopic condition various short long-term time point .</brief_summary>
	<brief_title>Autologous Unselected Hematopoietic Stem Cell Transplantation Refractory Crohn 's Disease</brief_title>
	<detailed_description>Crohn 's disease ( CD ) chronic , refractory inflammatory bowel disease affect entire digestive tract associate intestinal extra intestinal manifestation autoimmune disease . Conventional therapy Crohn 's disease isolate combination anti-inflammatory , immunosuppressant biologic drugs/corticosteroids . This treatment beneffit majority patient . However , proportion patient fail achieve complete long term disease control often require multiple intestinal surgery risk develop short bowel syndrome . Has propose Hematopoietic Stem Cell Transplantation ( HSCT ) proportionate lymphoablation reset immune system alternative strategy induce long term disease control high risk population . In study , it´s accept Crohn 's patient responsive conventional therapy . First , evaluate safety , clinical outcome . The selected patient admmited Bone Marrow Transplant ( BMT ) unit mobilize regimen submit Cyclophosphamide ( Cy ) 60mg/kg G-CSF 10mcg/kg day 5th day Cy harvest progenitor cell peripheral blood leukapheresis . After seven day rest condition regimen consist Cyclophosphamide 200mg/kg total dose 4 day globulin anti thymocyte rabbit 6,5mg/kg total dose 4 day methylprednisolone 500mg day . The clinical course patient refractory Crohn´s disease evaluate determine efficacy HSCT therapeutic tool , adverse aspect procedure clinical outcome quality life .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Gastroenteritis</mesh_term>
	<criteria>1 . Age 14 50 year ( patient age 50 70 participate principal investigator discretion ) . 2 . Confirmed diagnosis active Crohn 's disease : Diagnosis Crohn 's disease base typical radiological appearance typical histology least 6 month prior screen . Active disease time registration trial , define *Crohn 's Disease Activity Index ( CDAI ) &gt; 150 , ii ) Two follow : Harvey Bradshaw Index &gt; 4 Endoscopic evidence active disease confirm histology Clear evidence active small bowel Crohn 's disease Computed tomography ( CT ) Magnetic Resonance ( MR ) enterography . 3 . Unsatisfactory course despite immunosuppressive agent ( usually azathioprine , methotrexate two biologic agent ( usually infliximab , adalimumab and/or certolizumab ) addition corticosteroid . Patients relapse refractory disease despite thiopurines , methotrexate and/or infliximab/adalimumab/certolizumab maintenance therapy clear demonstration intolerance / toxicity drug . 4 . Current problem unsuitable surgery patient risk develop short bowel syndrome . 5 . Informed consent : Prepared undergo additional study procedure per trial schedule Patient undergone intensive counseling risk 1 . Pregnancy unwillingness use adequate contraception study , woman childbearing age . Unwillingness use appropriate contraceptive measure male . 2 . Concomitant severe disease renal : creatinine clearance &lt; 30 mL/min ( measure estimate ) cardiac : clinical evidence refractory congestive heart failure ; leave ventricular ejection fraction &lt; 40 % multigated radionuclide angiography ( MUGA ) cardiac echo ; chronic atrial fibrillation necessitate oral anticoagulation ; uncontrolled ventricular arrhythmia ; pericardial effusion hemodynamic consequence evaluate experienced echo cardiographer . pulmonary : diffusion capacity &lt; 40 % psychiatric disorder include active drug alcohol abuse concurrent recent history malignant disease ( exclude nonmelanoma skin cancer ) uncontrolled hypertension , define rest systolic blood pressure ≥ 140 and/or rest diastolic pressure ≥ 90 despite least 2 antihypertensive agent . uncontrolled acute chronic infection HIV , Human TLymphotropic virus ( HTLV1 2 ) , hepatitis virus infection investigator consider contraindication participation . chronic disease cause significant organ failure .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>autologous</keyword>
	<keyword>lymphoablation</keyword>
	<keyword>hematopoetic stem cell transplant</keyword>
	<keyword>immune system</keyword>
	<keyword>Bone marrow transplant</keyword>
</DOC>